Impact of Mexico on the Pharmaceutical Industry – Thematic Research
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Mexico pharmaceutical market was valued at $21.48 billion in 2020. Mexico has a large and rising middle-class population, a favorable environment for private sector investment, a rise in demand for healthcare services, and relatively high drug prices. The growth of the Mexican pharmaceutical market can be attributed to the large and growing middle-class population, the favorable environment for private sector investment, a rise in demand for healthcare services and pharmaceutical products, and increased quality certifications.
Low-cost manufacturing of pharmaceuticals is attracting increasing foreign investment to Mexico. Many US manufacturing companies aiming to reduce dependence on China perceive nearshoring to Mexico or Canada as even more advantageous than reshoring to the US. Since 2020, COVID-19-related supply chain disruptions have caused many US companies to take steps to bring some of their manufacturing closer to home.
Mexico pharmaceutical market overview
For more insights on this report, download a free report sample
What are the key market trends and drivers in the Mexico pharma industry?
The Mexico pharma industry grew significantly with the repeal of the “derecho de planta” law in 2010, part of the country’s economic liberalization under the conservative PAN party, which required all companies selling pharmaceuticals in Mexico to have a manufacturing facility in the country. Although the rising number of middle-class people in Mexico will fuel growing domestic pharma production, there will be limits to the fast pharma growth. Mexico is also heavily dependent on US markets, as the US is one of its best-trading partners.
There has been a trend toward outsourcing specialist operations and care to cut costs and enhance healthcare results. For example, in Mexico, most dialysis treatments are supplied by private corporations that are under contract with governmental healthcare institutions. Additionally, an increase in collaborations with US healthcare providers was observed to provide cardiac care, cancer treatment, and other specialist care in Mexican institutions or for patients to fly to the US. As a result, hospitals may save money on plants and equipment, materials, medications, and tools, while still having access to some of the most cutting-edge specialty surgical treatments.
What are the key deal types in the Mexico pharmaceutical market?
The key deal types in the Mexico pharmaceutical market are strategic alliances, mergers & acquisitions, contract service agreements, and capital raisings. The most common deal type was strategic alliances, followed by mergers and acquisitions (M&A). This is in line with general deal-making trends in pharma, where there tend to be more partnerships and funding than M&As.
Mexico pharmaceutical market, by deal types
For more deal type insights, download a free report sample
Which are the key companies in the Mexico pharma market?
Some of the key companies in the Mexico pharma market are F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., Boehringer Ingelheim International GmbH, Genomma Lab Internacional SAB de CV, Teva Pharmaceutical Industries Ltd, Laboratorios Serral SA de CV (a subsidiary of Endo International Plc), and Laboratorios Silanes SA de CV.
Market Report Scope
Market size (Year – 2020) |
$21.48 billion |
Key deal types | Strategic Alliances, Mergers & Acquisitions, Contract Service Agreement, and Capital Raisings |
Key pharma companies | Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., Boehringer Ingelheim International GmbH, Genomma Lab Internacional SAB de CV, Teva Pharmaceutical Industries Ltd, Laboratorios Serral SA de CV (a subsidiary of Endo International Plc), and Laboratorios Silanes SA de CV. |
Scope
- This report provides an assessment of the major industry, regulatory, macroeconomic, and technology trends shaping the Mexico pharma industry.
- It provides a detailed analysis of deals, clinical trials, marketed and pipeline products, and contract manufacturing.
- It also provides an overview of key regulatory and market access information, market drivers and barriers, and key players in the Mexican pharma sector.
Reasons to Buy
- See what trends are shaping the Mexican pharma market and driving innovation, including key government policies and strategic initiatives.
- Get an analysis of Mexico’s strong manufacturing and outsourcing sector, including plans to further strengthen these capabilities.
Table of Contents
Frequently asked questions
-
What was the Mexico pharmaceutical market size in 2020?
The Mexico pharmaceutical market was valued at $21.48 billion in 2020.
-
What are the key deal types in the Mexico pharmaceutical market?
The key deal types in the Mexico pharmaceutical market are strategic alliances, mergers & acquisitions, contract service agreements, and capital raisings.
-
Which are the key companies in the Mexico pharma market?
Some of the key companies in the Mexico pharma market are F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., Boehringer Ingelheim International GmbH, Genomma Lab Internacional SAB de CV, Teva Pharmaceutical Industries Ltd, Laboratorios Serral SA de CV (a subsidiary of Endo International Plc), and Laboratorios Silanes SA de CV.

Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Pharmaceuticals reports
